Actively Recruiting
Effectiveness of a Novel Smart Tag Technology in a Pharmacy-Led Setting to Improve Adherence, Patient-Centered Care and Outcomes in Hepatitis C
Led by University of Illinois at Chicago · Updated on 2025-04-10
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Illinois at Chicago
Lead Sponsor
S
Synchronyx
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of Tappt, a new digital medication companion app, for people with hepatitis C virus (HCV) who are starting daily oral medication in a pharmacy setting. This study aims to compare medication adherence, treatment completion, and sustained virologic response (SVR) rates between those using Tappt and a matched historical control group. It also seeks to understand how the app helps pharmacists personalize care based on patients' reported challenges with adherence and treatment. Participants in the study will download and use the Tappt app to track their adherence to oral HCV medications, such as glecaprevir/pibrentasvir or sofosbuvir/velpatasvir. Adherence is measured by how often participants scan passive tags on their medication compared to expected scans during their treatment period. After completing the study, researchers will compare the data collected from Tappt users to historical data from similar patients who did not use the app. During the study, participants will regularly use the Tappt app to record medication intake. Researchers will review medication adherence over 8 to 12 weeks, focusing on treatment completion and SVR achievement. The study is conducted in a clinical pharmacy setting where pharmacists manage treatment and use app data to support patient-centered care. Participation requires a smartphone and ability to communicate in English, with the study duration including initial treatment and follow-up assessments.
CONDITIONS
Brief Title
HCV Tappt Adherence Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosed with hepatitis C virus infection (positive HCV antibody and detectable HCV RNA)
- Starting oral hepatitis C therapy with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir
- Receiving HCV treatment managed by the clinical pharmacist at UI Health
- Access to a smartphone (iPhone 7 or later; Android from 2012 or later) with reliable data or Wi-Fi
- Able to understand and verbally communicate study protocol in English
- Willing and able to provide informed consent in English
You will not qualify if you...
- Unable to speak or read English
- Unable or unwilling to follow the study protocol
- Pregnant individuals
- Decompensated cirrhosis (Child Turcotte Pugh Class B and C)
- Hepatocellular carcinoma
- Prior liver or kidney transplant
- Unable or unwilling to consent
- Prisoners
- Individuals under 18 years of age
- No exclusion based on gender, race, or ethnic origin unless specified above in other criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 to 12 weeks
Participants use the Tappt app, a digital medication companion, to record adherence to their oral hepatitis C medication during their treatment period.
Visits as part of routine pharmacy-led treatment; app usage is ongoing throughout treatment
Trial Site Locations
Total: 1 location
1
UIH
Chicago, Illinois, United States, 60612
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here